Sonoma Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed Jun 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 16, 2026
SNOA$1.13+1.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page | ||
|---|---|---|
| PART I | ||
| ITEM 1. | Business | 1 |
| ITEM 1A. | Risk Factors | 18 |
| ITEM 1B. | Unresolved Staff Comments | 33 |
| ITEM 1C. | Cybersecurity | 33 |
| ITEM 2. | Properties | 34 |
| ITEM 3. | Legal Proceedings | 34 |
| ITEM 4. | Mine Safety Disclosures | 34 |
| PART II | ||
| ITEM 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 35 |
| ITEM 6. | [Reserved] | 35 |
| ITEM 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 35 |
| ITEM 7A. | Quantitative and Qualitative Disclosures About Market Risk | 40 |
| ITEM 8. | Consolidated Financial Statements and Supplementary Data | 41 |
| ITEM 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 42 |
| ITEM 9A. | Controls and Procedures | 42 |
| ITEM 9B. | Other Information | 42 |
| ITEM 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 42 |
| PART III | ||
| ITEM 10. | Directors, Executive Officers and Corporate Governance | 43 |
| ITEM 11. | Executive Compensation | 44 |
| ITEM 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 44 |
| ITEM 13. | Certain Relationships and Related Transactions, and Director Independence | 44 |
| ITEM 14. | Principal Accounting Fees and Services | 44 |
| PART IV | ||
| ITEM 15. | Exhibits, Financial Statement Schedules | 45 |
| Signatures | 49 | |
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.